Correspondence| June 21 2000 The Pro-115 → Gln mutation in peroxisome-proliferator-activated receptor (PPAR) γ2 is extremely rare in a large cohort of U.S. Caucasians Jonathan TERRETT; Jonathan TERRETT *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar John CHAMBERLAIN; John CHAMBERLAIN *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K.†Rayne Institute, Bone and Mineral Centre, Department of Medicine, Royal Free and University College Medical School, London WC1E 6JJ, U.K. Correspondence: Dr J. C. Chamberlain, Roche Products Ltd., 40 Broadwater Road, Welwyn Garden City, Herts., U.K. (e-mail chris.chamberlain@roche.com). Search for other works by this author on: This Site PubMed Google Scholar Sohaila RASTAN; Sohaila RASTAN *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Richard MARSHALL; Richard MARSHALL *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Ralph MCGINNIS; Ralph MCGINNIS *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Nigel SPURR; Nigel SPURR *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Eamonn O'BRIEN; Eamonn O'BRIEN *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Catherine EVANS; Catherine EVANS *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Andrew RUT Andrew RUT *Biotechnology and Genetics, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, Essex CM19 5AW, U.K. Search for other works by this author on: This Site PubMed Google Scholar Clin Sci (Lond) (2000) 99 (1): 89–90. https://doi.org/10.1042/cs0990089 Article history Received: October 27 1999 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation Jonathan TERRETT, John CHAMBERLAIN, Sohaila RASTAN, Richard MARSHALL, Ralph MCGINNIS, Nigel SPURR, Eamonn O'BRIEN, Catherine EVANS, Andrew RUT; The Pro-115 → Gln mutation in peroxisome-proliferator-activated receptor (PPAR) γ2 is extremely rare in a large cohort of U.S. Caucasians. Clin Sci (Lond) 1 July 2000; 99 (1): 89–90. doi: https://doi.org/10.1042/cs0990089 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Science Search Advanced Search Keywords: obesity, pharmacogenetics, point mutation, type II diabetes mellitus, transcription factors This content is only available as a PDF. The Biochemical Society and the Medical Research Society © 20002000 Article PDF first page preview Close Modal You do not currently have access to this content.